Life science research tools supplier Abcam said Monday it had acquired Calico in a bid to boost the company's catalogue of high-quality recombinant rabbit monoclonal antibodies.

Under the agreement, Calico would make its range of recombinant CAL antibodies available at both research and commercial scale, through the Abcam global commercial network.

Financial terms of the transaction were not disclosed and were expected to have a 'minimal impact' on revenue and earnings for 2019, Abcam said.

'Abcam expands its offering of rabbit monoclonals for IHC, allowing development of more products for their most important targets, faster,' said John Baker, SVP of Product Portfolio and Innovation at Abcam.